Contrasting Big Cypress Acquisition (OTCMKTS:BCYP) & Passage Bio (NASDAQ:PASG)

Passage Bio (NASDAQ:PASG) and Big Cypress Acquisition (OTCMKTS:BCYP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for Passage Bio and Big Cypress Acquisition, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	0	0	3	0	3.00
Big Cypress Acquisition	0	0	0	0	0.00

Passage Bio presently has a consensus target price of $9.00, indicating a potential upside of 1,579.10%. Given Passage Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than Big Cypress Acquisition.

Institutional & Insider Ownership

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 60.2% of Big Cypress Acquisition shares are owned by institutional investors. 4.3% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Passage Bio and Big Cypress Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-72.53%	-52.10%
Big Cypress Acquisition	N/A	N/A	N/A

Valuation & Earnings

This table compares Passage Bio and Big Cypress Acquisition”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$102.06 million	($1.17)	-0.46
Big Cypress Acquisition	N/A	N/A	-$10,000.00	N/A	N/A

About Passage Bio

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About Big Cypress Acquisition

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.